Navigation Links
Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
Date:8/4/2009

SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.

The single-blind, placebo-controlled Phase 2 study is designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP's ability to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function. The study is expected to enroll approximately 30 to 40 patients in the United States, Germany and Israel and will examine up to 3 doses of CD-NP.

"Currently there is a significant unmet need in acute heart failure for treatments that can both relieve symptoms and also preserve or enhance renal function in these patients," said Dr. James Young, MD, George & Linda Kaufman Chair and Professor, Cleveland Clinic, and the principal investigator on the study. "The potential of CD-NP to meet both of these objectives is a compelling scientific story, and is of particular clinical importance for the approximately two-thirds of heart failure patients with pre-existing renal dysfunction."

Previously reported results of a Phase 1b study in chronic heart failure patients showed that CD-NP infusion was associated with an improvement in renal function. Previously reported interim results from the first cohort of a Phase 2a study in patients hospitalized for acute heart failure also showed that CD-NP infusion was associated with clinically meaningful improvements in car
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Exercise of Overallotment
2. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
3. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
4. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
5. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
6. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
8. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
9. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
10. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
11. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  The University of ... Biosciences (CCE/Bio) and UC San Diego Extension announced ... be held Aug.  12 – 14, 2015, at ... three-day workshop provides an intense exposure to best ... and is well-suited to biologists, process engineers and ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter ... — a revolutionary new archwire that allows orthodontists to simultaneously apply different forces ... the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to ...
(Date:6/29/2015)... ... , ... The global microfluidics market is expected to grow ... 2020). The market is mainly driven by the rising geriatric population, growing Asian ... of adequate healthcare and research infrastructure in emerging markets, dearth of skilled professionals ...
(Date:6/29/2015)... June 29, 2015 According to a ... XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other ... Companies, CRO) - Global Forecast to 2020", published by MarketsandMarkets, ... by 2020 from $107.56 Million in 2015, at a CAGR ... ables and 67 F igures spread through ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4
... PRINCETON, New Jersey and SAN DIEGO,California, September 8 , ... for Continuous Process,Chemistry Technologies and for Further Global Expansion, ... investment of $3.3M,by a group of private and financial ... Graphisoft and Dave Tapolczay, CEO of Medical,Research Council Technology ...
... announced that it has appointed A.J. Whalen as Solutions Director. ... ... 8, 2008 -- www.symphony-consulting.com [Symphony Management Consulting] announced ... , , ,Mr. Whalen joins Symphony from Wellesley Information Services ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTICD ; ... a letter from the Listing Qualifications Staff of ... is not in compliance with the,$50,000,000 minimum market ... Marketplace Rule 4450(b)(1)(A). Furthermore, the Company does not,comply ...
Cached Biology Technology:World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round 2Symphony Managemnt Consulting Hires New Solutions Director 2CTI Receives NASDAQ Letter 2CTI Receives NASDAQ Letter 3
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... termites use vibrations to choose the wood they eat ... in homes and also may provide insights into the ... most noise but have some signals that trigger attention ... entomologist Theo Evans says laboratory experiments have found that ...
... A team of Fox Chase Cancer Center scientists led ... genetic mutation that keeps a mouse strain from developing ... The report by Kappes and his colleagues appears in ... first discovered the mice with this naturally occurring defect ...
... 2,or ACC2, appears to turn the adipose or fat ... the animals can eat more and weigh less,than their ... appears online today in the Proceedings of the National,Academy ... mice bred to lack ACC2," said Dr. Salih,Wakil, chair ...
Cached Biology News:Termites feed through good vibrations 2Fox Chase Cancer Center scientists identify immune-system mutation 2Lack of enzyme turns fat cells into fat burners 2